<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396484</url>
  </required_header>
  <id_info>
    <org_study_id>Methyldopa</org_study_id>
    <secondary_id>UC4DK106993</secondary_id>
    <secondary_id>UC4DK117009</secondary_id>
    <nct_id>NCT03396484</nct_id>
  </id_info>
  <brief_title>Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes</brief_title>
  <acronym>TN-23</acronym>
  <official_title>Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study is to see if methyldopa can change the immune system's attack on insulin producing&#xD;
      cells in people at early stages of type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double blinded, placebo-controlled, multi-center crossover&#xD;
      clinical trial.&#xD;
&#xD;
      Eligible subjects will be randomized in a 1:1 allocation ratio to one of two treatment&#xD;
      schedules: first methyldopa then placebo vs. first placebo then methyldopa.&#xD;
&#xD;
      The study objective is to assess the safety, efficacy, and mode of action of methyldopa to&#xD;
      reduce DQ8 antigen presentation in individuals at Stage 1 and 2 of type 1 diabetes (T1D).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study not begun due to continued laboratory work on the feasibility of outcome measures.&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DQ8 Antigen Presentation</measure>
    <time_frame>6 months after initiation of treatment</time_frame>
    <description>insulin peptide-specific DQ8 antigen presentation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Methyldopa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day&#xD;
Children: methyldopa dose based on weight twice daily for one week then increased to three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive agent to match active drug in appearance and dose frequency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methyldopa</intervention_name>
    <description>Tablet for oral dosing</description>
    <arm_group_label>Methyldopa</arm_group_label>
    <other_name>Aldomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet for oral dosing</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant in TrialNet Pathway to Prevention Study (TN01)&#xD;
&#xD;
          -  Willing to provide Informed Consent or, if the subject is &lt;18 years of age, have a&#xD;
             parent or legal guardian provide Informed Consent&#xD;
&#xD;
          -  Confirmed positive for one or more autoantibodies, one of which is insulin&#xD;
             autoantibody (mIAA)&#xD;
&#xD;
          -  Positive for at least one gene encoding HLA-DQ8 (DQB*0302)&#xD;
&#xD;
          -  If a female participant with reproductive potential, willing to avoid pregnancy and&#xD;
             undergo pregnancy testing prior to randomization and during the study&#xD;
&#xD;
          -  Have normal or abnormal glucose tolerance on OGTT performed within 7 weeks of&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness of a participant to give written informed consent or comply&#xD;
             with study protocol&#xD;
&#xD;
          -  History of clinically significant anemia or Hemoglobin &lt;10 g/dl&#xD;
&#xD;
          -  Evidence of liver dysfunction&#xD;
&#xD;
          -  History of renal insufficiency&#xD;
&#xD;
          -  History of symptomatic hypotension including positional hypotension&#xD;
&#xD;
          -  Systolic BP &lt; 100 mmHg for adults or blood pressure &lt; 5th percentile for&#xD;
             age/height/gender in children and adolescents&#xD;
&#xD;
          -  Use of a treatment that is known to cause a significant, ongoing change in the course&#xD;
             of diabetes or immunologic status, within 4 weeks prior to participation. This&#xD;
             includes high-dose inhaled, extensive topical or systemic glucocorticoids&#xD;
&#xD;
          -  Females who are pregnant at the time of screening, breastfeeding or unwilling to defer&#xD;
             pregnancy during the 16-month study period. (Female participant must be at least 100&#xD;
             days postpartum before enrollment into study)&#xD;
&#xD;
          -  Unable to avoid concurrent antihypertensive medications, monoamine oxidase (MAO)&#xD;
             inhibitors, lithium, or medications containing ferrous sulfate or ferrous gluconate&#xD;
&#xD;
          -  Unable to avoid medications that affect stomach pH, such as proton pump inhibitors or&#xD;
             histamine H2 receptor blockers&#xD;
&#xD;
          -  Past or current medical problems or findings from physical examination or laboratory&#xD;
             testing that are not listed above, which, in the opinion of the investigator, may pose&#xD;
             additional risks from participation in the study, may interfere with the participant's&#xD;
             ability to comply with study requirements or that may impact the quality or&#xD;
             interpretation of the data obtained from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Greenbaum, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Type 1 Diabetes TrialNet</affiliation>
  </overall_official>
  <link>
    <url>https://www.trialnet.org/</url>
    <description>TrialNet Public Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TrialNet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyldopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

